Related Experiment Video

Updated: May 23, 2026

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

[Therapeutic trials for Duchenne muscular dystrophy: between hopes and disappointments]

Clemens Bloetzer1, Joël Fluss, Pierre-Yves Jeannet

  • 1Consultation des maladies neuromusculaires, Unité de neuropédiatrie et de neuroréhabilitation pédiatrique, DMCP, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|March 22, 2012
PubMed

Insights

Three novel Duchenne muscular dystrophy therapies targeting specific genetic mutations and a broad pharmacological approach are in clinical trials. These Duchenne muscular dystrophy treatments offer new hope for patients and raise important research questions.

Area of Science:

  • Genetics
  • Neurology
  • Pharmacology

Context:

  • Duchenne muscular dystrophy (DMD) is a severe X-linked inherited muscle-wasting disease.
  • The discovery of the dystrophin gene has paved the way for targeted therapeutic development.
  • Current research focuses on innovative strategies to address the underlying genetic defects in DMD.

Purpose:

  • To introduce three promising Duchenne muscular dystrophy therapies currently in clinical trials.
  • To highlight the mechanisms of action for each therapeutic strategy.
  • To discuss the implications and open questions arising from these early clinical trials.

Summary:

  • The paper details three advanced therapeutic strategies for Duchenne muscular dystrophy: read-through of premature stop codons, exon skipping, and a mutation-agnostic pharmacological approach.
  • The first two strategies represent personalized medicine, targeting specific genetic mutations in DMD patients.
  • The third approach offers a broader potential application, benefiting all individuals with Duchenne muscular dystrophy.

Impact:

  • These clinical trials represent significant advancements in Duchenne muscular dystrophy treatment.
  • The development of personalized and broad-acting therapies offers new hope for patients and families.
  • The study prompts further research and discussion on the future of DMD therapeutics and patient care.

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...